NR3C2 and metabolic dysfunction-associated steatotic liver disease: These findings suggest that MR blockade with spironolactone may exert additive or synergistic effects when combined with antioxidant therapy in MASLD, particularly with respect to insulin resistance and noninvasive markers of hepatic inflammation and steatosis [51].